X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (568) 568
guanine - analogs & derivatives (488) 488
male (353) 353
animals (347) 347
index medicus (336) 336
female (275) 275
pharmacology & pharmacy (249) 249
oncology (206) 206
guanine - pharmacokinetics (204) 204
pemetrexed (195) 195
adult (169) 169
middle aged (165) 165
guanine - administration & dosage (164) 164
rats (137) 137
pharmacokinetics (135) 135
aged (134) 134
mice (130) 130
glutamates - administration & dosage (108) 108
guanine - pharmacology (105) 105
guanine - therapeutic use (102) 102
guanine - adverse effects (101) 101
chemotherapy (97) 97
dose-response relationship, drug (95) 95
guanine - metabolism (90) 90
cancer (85) 85
antineoplastic combined chemotherapy protocols - therapeutic use (81) 81
treatment outcome (79) 79
glutamates - pharmacokinetics (78) 78
antiviral agents - pharmacokinetics (77) 77
research (75) 75
guanine (72) 72
therapy (69) 69
lung neoplasms - drug therapy (68) 68
glutamates - adverse effects (64) 64
carcinoma, non-small-cell lung - drug therapy (61) 61
cell line, tumor (61) 61
biochemistry & molecular biology (60) 60
neoplasms - drug therapy (58) 58
acyclovir (56) 56
antiviral agents - therapeutic use (56) 56
9-guanine (55) 55
research article (55) 55
antineoplastic combined chemotherapy protocols - adverse effects (53) 53
kinetics (52) 52
toxicology (51) 51
antineoplastic agents - pharmacokinetics (50) 50
article (50) 50
metabolism (50) 50
drug therapy (49) 49
guanine - blood (49) 49
guanine - chemistry (49) 49
pharmacology (49) 49
tissue distribution (49) 49
chromatography, high pressure liquid (48) 48
glutamates - pharmacology (48) 48
glutamates - therapeutic use (48) 48
health aspects (48) 48
care and treatment (47) 47
cell lung-cancer (47) 47
child (47) 47
entecavir (47) 47
rats, sprague-dawley (47) 47
time factors (46) 46
adolescent (45) 45
antineoplastic combined chemotherapy protocols - pharmacokinetics (44) 44
drug administration schedule (44) 44
gemcitabine (44) 44
antineoplastic agents - pharmacology (42) 42
antiviral agents - pharmacology (42) 42
analysis (41) 41
cisplatin (40) 40
hepatitis b, chronic - drug therapy (40) 40
pharmacology/toxicology (40) 40
antiviral agents - administration & dosage (39) 39
half-life (39) 39
area under curve (38) 38
antiviral agents - adverse effects (37) 37
dna (37) 37
6-mercaptopurine (36) 36
multitargeted antifolate (36) 36
resistance (36) 36
thymidylate synthase (36) 36
administration, oral (35) 35
cells, cultured (35) 35
efficacy (35) 35
guanine nucleotides - blood (35) 35
microbiology (35) 35
toxicity (35) 35
cells (34) 34
antimetabolites, antineoplastic - pharmacokinetics (33) 33
biotransformation (33) 33
dosage and administration (33) 33
expression (33) 33
lung neoplasms - pathology (33) 33
aged, 80 and over (32) 32
chemistry, analytical (32) 32
chemistry, medicinal (32) 32
clinical trials as topic (32) 32
dna - metabolism (32) 32
dna damage (32) 32
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (854) 854
French (4) 4
Japanese (4) 4
Chinese (1) 1
German (1) 1
Korean (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Nakase, H and Motoya, S and Matsumoto, T and Watanabe, K and Hisamatsu, T and Yoshimura, N and Ishida, T and Kato, S and Nakagawa, T and Esaki, M and Nagahori, M and Matsui, T and Naito, Y and Kanai, T and Suzuki, Y and Nojima, M and Watanabe, M and Hibi, T and Andoh, Akira and Ashida, Toshifumi and Endo, Katsuya and Endo, Yutaka and Esaki, Motohiro and Fujita, Hiroshi and Fujiya, Mikihiro and Haruma, Ken and Hibi, Toshifumi and Hiraoka, Sakiko and Hirata, Ichiro and Hisamatsu, Tadakazu and Honda, Yutaka and Iijima, Hideki and Iizuka, Bunei and Ikeya, Kentaro and Inoue, Takuya and Inoue, Shuji and Ishida, Tetsuya and Ishiguro, Yo and Ishihara, Shunji and Ito, Hiroaki and Iwakiri, Ryuichi and Kagaya, Takashi and Kanai, Takanori and Kashida, Hiroshi and Kato, Shingo and Kato, Jun and Katsurada, Takehiko and Kinjyo, Fukunori and Kobayashi, Kiyonori and Kodama, Mayumi and Kunisaki, Reiko and Kurahara, Koichi and Kurokami, Takafumi and Kyouwon, Lee and Matsuda, Koichiro and Matsueda, Kazuhiro and Matsui, Toshiyuki and Matsumoto, Takayuki and Mitsuyama, Keiichi and Mizokami, Yuji and Motoya, Satoshi and Naito, Yuji and Nakagawa, Tomoo and Nakamura, Shiro and Nakase, Hiroshi and Nojima, Masanori and Nomura, Masafumi and Ogawa, Atsuhiro and Okazaki, Kazuichi and Otsuka, Kazuaki and Sakuraba, Hirotake and Saruta, Masayuki and Sasaki, Makoto and Shirai, Takayuki and Suga, Tomoaki and Sugimura, Kazuhito and Sugiyama, Toshiro and Suzuki, Yasuo and Takeshima, Fuminao and Tamaki, Hiroyuki and Tanaka, Shinji and Tanida, Satoshi and Tominaga, Keiichi and Tomizawa, Taku and Watanabe, Kenji and Watanabe, Mamoru and Yamamoto, Shojiro and Yamashita, Masaki and Yoshida, Atsushi and Yoshimura, Naoki and DIAMOND Study Grp and DIAMOND study group
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2017, Volume 46, Issue 9, pp. 873 - 882
Summary Background Significance of monitoring adalimumab trough levels and anti‐adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD)... 
RHEUMATOID-ARTHRITIS | MAINTENANCE | INFLAMMATORY-BOWEL-DISEASE | 6-THIOGUANINE NUCLEOTIDE | IMMUNOMODULATORS | COMBINATION THERAPY | ULCERATIVE-COLITIS | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Guanine Nucleotides - blood | Adalimumab - immunology | Thionucleotides - blood | Humans | Anti-Inflammatory Agents - immunology | Male | Treatment Outcome | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - therapeutic use | Mercaptopurine - therapeutic use | Adalimumab - blood | Crohn Disease - blood | Crohn Disease - drug therapy | Sensitivity and Specificity | Adalimumab - pharmacokinetics | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - pharmacokinetics | Antibodies - blood | Female | Drug Therapy, Combination | Mercaptopurine - analogs & derivatives | Measurement | Viral antibodies | Medical research | Analysis | Medicine, Experimental | Antibodies | Biopharmaceutics | Blood cells | Body weight | Erythrocytes | Diamonds | Crohn's disease | Pharmacology | Regression analysis | Thioguanine | Patients | Crohns disease | Sensitivity | Regression models | Red blood cells | Multiple regression models | Predictions | Monoclonal antibodies | Remission | Pharmacokinetics | Original | Personalised Adalimumab Pharmacokinetics
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
Therapeutic drug monitoring, ISSN 0163-4356, 2004, Volume 26, Issue 3, pp. 311 - 318
Journal Article
Journal Article
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, ISSN 0269-2813, 04/2016, Volume 43, Issue 8, pp. 863 - 883
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 07/2011, Volume 7, Issue 7, pp. 919 - 928
Introduction: Pemetrexed is a multi-targeted antifolate cytotoxic agent that has demonstrated activity in a number of very common cancer types including NSCLC... 
pemetrexed | CNS distribution | NSAID | antimetabolite | pharmacokinetic | third-space fluid | renal impairment | ADVANCED SOLID TUMORS | EVERY 21 DAYS | MULTITARGETED ANTIFOLATE MTA | BIOCHEMISTRY & MOLECULAR BIOLOGY | BODY-SURFACE AREA | CONTINUAL REASSESSMENT METHOD | PHASE-I EVALUATION | MALIGNANT PLEURAL MESOTHELIOMA | FOLIC-ACID | CELL LUNG-CANCER | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | Folic Acid Antagonists - administration & dosage | Guanine - analogs & derivatives | Humans | Drug Evaluation | Antineoplastic Agents - administration & dosage | Platinum Compounds - pharmacokinetics | Tissue Distribution | Drug Interactions | Liver - drug effects | Antineoplastic Agents - pharmacokinetics | Folic Acid Antagonists - pharmacokinetics | Disease Models, Animal | Guanine - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols | Glutamates - pharmacokinetics | Pemetrexed | Mesothelioma - drug therapy | Brain - drug effects | Vitamins - pharmacokinetics | Animals | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Glutamates - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Kidney Neoplasms - drug therapy | Vitamins - administration & dosage | Guanine - administration & dosage
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 4/2013, Volume 112, Issue 2, pp. 247 - 255
Brain metastases (BM) and leptomeningeal metastases (LM) are devastating neurologic complications. Pemetrexed is a multi-targeted anti-folate agent approved... 
Neurology | Medicine & Public Health | Oncology | Brain metastases | Pharmacokinetics | Leptomeningeal metastases | Pemetrexed | ADVANCED BREAST-CANCER | MANAGEMENT | DOSE INTRAVENOUS METHOTREXATE | CHEMOTHERAPY | CLINICAL NEUROLOGY | TEMOZOLOMIDE | CELL LUNG-CANCER | PHASE-II TRIAL | ONCOLOGY | TOPOTECAN | CLINICAL-PRACTICE GUIDELINE | NEOPLASTIC MENINGITIS | Glutamates - therapeutic use | Prognosis | Antimetabolites, Antineoplastic - pharmacokinetics | Follow-Up Studies | Guanine - analogs & derivatives | Humans | Middle Aged | Glutamates - cerebrospinal fluid | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Tissue Distribution | Guanine - cerebrospinal fluid | Brain Neoplasms - secondary | Antimetabolites, Antineoplastic - blood | Meningeal Neoplasms - drug therapy | Adult | Female | Glutamates - blood | Brain Neoplasms - mortality | Guanine - therapeutic use | Guanine - pharmacokinetics | Neoplasms - mortality | Glutamates - pharmacokinetics | Survival Rate | Brain Neoplasms - drug therapy | Disease Progression | Meningeal Neoplasms - mortality | Neoplasms - drug therapy | Antimetabolites, Antineoplastic - cerebrospinal fluid | Antimetabolites, Antineoplastic - therapeutic use | Guanine - blood | Pilot Projects | Aged | Neoplasm Staging | Neoplasms - pathology | Meningeal Neoplasms - secondary | Complications and side effects | Care and treatment | Chemotherapy | Development and progression | Metastasis | Methotrexate | Lung cancer, Non-small cell | Folic acid | Cancer | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 955 - 968
LY2603618 is an inhibitor of checkpoint kinase 1 (CHK1), an important regulator of the DNA damage checkpoints. Preclinical experiments analyzed NCI-H2122 and... 
Medicine & Public Health | CHK1 | Lung cancer | Cell cycle | Oncology | LY2603618 | Pharmacology/Toxicology | Pharmacokinetics | Cancer | PLUS CISPLATIN | DNA-DAMAGE | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | FLUOROURACIL | GEMCITABINE | CELL LUNG-CANCER | CHECKPOINT KINASE-1 | ONCOLOGY | ABROGATION | PHARMACOLOGY & PHARMACY | Cisplatin - pharmacokinetics | Glutamates - adverse effects | Antineoplastic Combined Chemotherapy Protocols - blood | Guanine - analogs & derivatives | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Neoplasms - blood | Phenylurea Compounds - adverse effects | Adult | Cisplatin - blood | Female | Glutamates - blood | Guanine - adverse effects | Phenylurea Compounds - pharmacokinetics | Guanine - pharmacokinetics | Glutamates - pharmacokinetics | Phenylurea Compounds - blood | DNA - metabolism | Pemetrexed | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Guanine - blood | Animals | Phenylurea Compounds - administration & dosage | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Cell Line, Tumor | Cisplatin - adverse effects | Glutamates - administration & dosage | Aged | Neoplasms - pathology | Pyrazines - blood | Guanine - administration & dosage | Complications and side effects | DNA damage | Development and progression | Research | Risk factors | Studies | Pharmacology | Inhibitor drugs | Cancer therapies | Analysis | Reaction kinetics | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2010, Volume 16, Issue 10, pp. 2872 - 2880
Journal Article
Journal Article
Journal of Crohn's & colitis, ISSN 1873-9946, 2018, Volume 12, Issue 12, pp. 1410 - 1417
Journal Article